retatrutide phase 2 trial type 2 diabetes weight loss triple hormone receptor agonist Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A # New GLP-3 drug significantly slashes

The challenge: eating enough protein with reduced appetite Here is the catch

Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US

Why starting low matters The escalation protocol is not arbitrary

Differences between two groups were determined by the unpaired Student's t-test, and differences between multiple groups were determined by one-way analysis of variance followed by Fisher's least significant difference test

i3-i14, academic.oup.com/ckj/article/5/Suppl_1/i3/447534

GCGR co-agonism is the key structural differentiator from tirzepatide